Company Description
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome.
The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018.
Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Dec 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 134 |
| CEO | Omid Farokhzad |
Contact Details
Address: 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 453 0000 |
| Website | seer.bio |
Stock Details
| Ticker Symbol | SEER |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001726445 |
| CUSIP Number | 81578P106 |
| ISIN Number | US81578P1066 |
| Employer ID | 82-1153150 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, Chief Executive Officer, and Chair of the Board of Directors |
| David R. Horn | President,Treasurer and Chief Financial Officer |
| Kenny Ross | Chief Operations and Product Officer |
| Marissa Dixon | Chief People Officer |
| Dr. Serafim Batzoglou Ph.D. | Chief Data Officer |
| Martin Goldberg Ph.D. | Senior Vice President of Product Development |
| Dr. Asim Siddiqui Ph.D. | Senior Vice President of Research and Tech Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 144 | Filing |
| May 28, 2025 | ARS | Filing |
| May 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 28, 2025 | DEF 14A | Other definitive proxy statements |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Mar 3, 2025 | 10-K | Annual Report |